Editas Medicine (EDIT) Research & Development (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Research & Development of $19.8 million for Q3 2025, down 58.49% year-over-year from $47.6 million in Q3 2024, and up 22.21% quarter-over-quarter from $16.2 million in Q2 2025.
Editas Medicine (EDIT) Research & Development (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Research & Development for 11 consecutive years, with $19.8 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Research & Development fell 58.49% year-over-year to $19.8 million; the TTM figure through Sep 2025 stood at $111.2 million (down 49.52% YoY), while the FY2024 annual figure was $199.2 million, up 12.16% from the prior year.
- Research & Development advanced to $19.8 million in Q3 2025 per EDIT's latest filing, from $16.2 million in the prior quarter.
- Across five years, Research & Development topped out at $69.6 million in Q4 2023 and bottomed at $16.2 million in Q2 2025.
- Historically, Research & Development has averaged $39.8 million across 5 years, with a median of $40.5 million in 2023.
- Annual changes were most pronounced in 2024 — Research & Development jumped 82.04% — and 2025, when it plunged 70.15%.
- Editas Medicine's Research & Development stood at $37.6 million in 2021, then jumped by 38.47% to $52.0 million in 2022, then surged by 33.77% to $69.6 million in 2023, then sank by 30.11% to $48.6 million in 2024, then plunged by 59.32% to $19.8 million in 2025.
- Business Quant data shows EDIT's Research & Development at $19.8 million in Q3 2025, $16.2 million in Q2 2025, and $26.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 19.78 Mn |
| Jun 30, 2025 | 16.18 Mn |
| Mar 31, 2025 | 26.59 Mn |
| Dec 31, 2024 | 48.61 Mn |
| Sep 30, 2024 | 47.64 Mn |
| Jun 30, 2024 | 54.21 Mn |
| Mar 31, 2024 | 48.79 Mn |
| Dec 31, 2023 | 69.56 Mn |
| Sep 30, 2023 | 40.51 Mn |
| Jun 30, 2023 | 29.78 Mn |
| Mar 31, 2023 | 37.80 Mn |
| Dec 31, 2022 | 52.00 Mn |
| Sep 30, 2022 | 41.33 Mn |
| Jun 30, 2022 | 43.66 Mn |
| Mar 31, 2022 | 37.98 Mn |
| Dec 31, 2021 | 37.55 Mn |
| Sep 30, 2021 | 29.27 Mn |
| Jun 30, 2021 | 33.75 Mn |
| Mar 31, 2021 | 41.94 Mn |
| Dec 31, 2020 | 61.50 Mn |